Third Harmonic Bio, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Third Harmonic Bio, Inc. has commenced its voluntary liquidation and dissolution, leading to the delisting of its common stock from Nasdaq and the termination of its SEC reporting obligations.
8-K: Third Harmonic Bio Initiates Voluntary Liquidation and Delisting, Announces Shareholder Distribution
Third Harmonic Bio, Inc. is proceeding with its voluntary liquidation and dissolution, including delisting from Nasdaq, deregistering its common stock, and authorizing an initial liquidation distribution of $5.35 per share.
Third Harmonic Bio, Inc. is proceeding with its liquidation and dissolution, anticipating an initial shareholder distribution of $5.30 to $5.35 per share, while actively pursuing the sale of its lead asset, THB335, following positive Phase 1 clinical data.
Third Harmonic Bio, Inc. announced that its stockholders have approved the liquidation and dissolution of the company, alongside the election of directors and ratification of its accounting firm, during its 2025 Annual Meeting.
Third Harmonic Bio, Inc. announces the departure of Chief Scientific Officer Christopher Dinsmore, effective April 21, 2025, with a separation agreement in place.
8-K: Third Harmonic Bio Announces Plan to Dissolve, Liquidate, and Distribute Assets to Stockholders
Third Harmonic Bio plans to dissolve, liquidate its assets, and distribute the remaining cash to stockholders, with an initial distribution estimated between $5.13 and $5.33 per share expected in Q3 2025.
Third Harmonic Bio reports its year-end 2024 financial results, highlights the advancement of THB335 into Phase 2 trials, and announces a strategic alternatives process.
Third Harmonic Bio is progressing its THB335 drug candidate for mast cell-mediated inflammatory diseases towards a Phase 2 trial while simultaneously exploring strategic alternatives to maximize shareholder value.
Third Harmonic Bio reveals a restructuring plan involving workforce reduction and provides an update on its preliminary cash position.
Third Harmonic Bio announced its third quarter 2024 financial results, highlighting a strong cash position and progress in its THB335 Phase 1 clinical trial.
8-K: Third Harmonic Bio Reports Second Quarter 2024 Financial Results and Provides Clinical Trial Update
Third Harmonic Bio announced its second quarter 2024 financial results, highlighted by a strong cash position and an update on the progress of its THB335 Phase 1 clinical trial.
Third Harmonic Bio reports the resignation of a director and the results of its 2024 Annual Meeting, including the election of two new directors and ratification of its accounting firm.
Third Harmonic Bio reports a strong financial position and progress in clinical trials, including the initiation of a Phase 1 study for THB335.
Third Harmonic Bio has appointed Geoff McDonough, M.D., to its Board of Directors, bringing extensive operational and clinical experience.
Third Harmonic Bio announced its fourth quarter and full year 2023 financial results, highlighting a strong cash position and the filing of a U.S. IND for THB335.